Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

marketing rights for XARELTO®, and is supported by the Bayer HealthCare U.S. sales force.

For more information about XARELTO®, visit www.xarelto-us.com. The XARELTO® CarePath™ Support Program is a resource designed for health care providers, patients and caregivers. Visit www.xareltocarepath.com or call 1-888-XARELTO to learn more about the XARELTO® CarePath™ resources focused on access, education and adherence.

Important Safety Information

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?

  • For people taking XARELTO® for atrial fibrillation:
    People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO® lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO®, you may have increased risk of forming a clot in your blood.
    Do not stop taking XARELTO® without talking to the doctor who prescribes it for you. Stopping XARELTO® increases your risk of having a stroke.
    If you have to stop taking XARELTO®, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming.
  • XARELTO® can cause bleeding, which can be serious, and rarely may lead to death. This is because XARELTO® is a blood thinner medicine that reduces blood clotting. While you take XARELTO® you are likely to bruise more easily and it may take longer for bleeding to stop

You may have a higher risk of bleeding if you take XARELTO<
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... t:slim® and t:flex™ Insulin Pumps, today announced the pricing ... its common stock at a price to the public ... from this offering are expected to be $56.3 million, ... offering expenses payable by Tandem. All of the shares ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... , Feb. 26, 2015  BD Life Sciences, a ... BDX ), a leading global medical ... focused on enabling high-resolution biology, today announced that ... for highly multiplexed cell isolation and single-cell gene ... BD,s powerful BD FACS™ single-cell sorting instrumentation and ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... YORK, Dec. 15, 2011  New York University and the ... they have appointed Theodore (Ted) Rappaport, 51, to lead ... Rappaport, currently the William and Bettye ... at Austin (UTA), is a leading educator and entrepreneur ...
... 15, 2011  Today, the Consumer Healthcare Products Association (CHPA), announced ... Five Moms campaign to raise awareness of ... of two teenage boys and a high school math teacher ... the dangers of substance abuse. Millions of ...
Cached Medicine Technology:Wireless Engineering Pioneer Joins NYU-Poly and NYU 2Wireless Engineering Pioneer Joins NYU-Poly and NYU 3Wireless Engineering Pioneer Joins NYU-Poly and NYU 4CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
(Date:2/27/2015)... February 27, 2015 Jvion announced ... is collaborating with the Atlanta-based software company through ... of Jvion’s advanced predictive capabilities suite within the ... that identifies and prevents financial and clinical losses ... predictions that help prevent patient deterioration and suffering, ...
(Date:2/27/2015)... WI (PRWEB) February 27, 2015 UAS ... Adult Cubes, at Natural Products Expo West, March 6 ... are very excited to release the hands down best ... cream taste with an extra zing of Vitamin C. ... Cubes, winner of the NutrAward 2014, Delicious Living’s Supplement ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Aligned ... five local neighborhood health centers, officially welcomes Dr. ... Medicine based in Aligned Modern Health’s Lincoln Square, ... graduated from the National University of Health Sciences ... Award. She has completed post-graduate coursework in ...
(Date:2/27/2015)... 2015 The purpose of the Rouche ... to explore the current use of 3D printing in ... contribute to the Survey about 3D Printing please go ... use among large and small companies from a wide ... recent PwC and Manufacturing Institute survey of 3D Printing ...
Breaking Medicine News(10 mins):Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 3Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 3
... procedures, survey shows , FRIDAY, July 31 (HealthDay News) -- ... visited a plastic surgeon for a "makeover" -- a ... around her lips and at the corners of her mouth. ... might lose her competitive edge in a tightening job market. ...
... , , WASHINGTON, July 31 ... Tobacco-Free Kids: , , (Logo: ... Council has taken an important step to protect the District,s kids and ... tax by 50 cents to $2.50 per pack - the seventh highest ...
... Fla., July 31 Sanofi-aventis US announced yesterday that the FDA ... in the USA. It offers results that last for years. Dr ... the product while abroad. It was approved in Europe(CE) for over ... global pharmaceutical company. The FDA approval is based on results from ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , ... Administration (FDA) today approved the first and only antipsychotic for ... were approved for the acute treatment of schizoaffective disorder either ... INVEGA(R) was approved in 2006 for the treatment of schizophrenia. ...
... , Campaign Officially Launches ... months of college students and others wrestling with the creative challenge ... for its nationwide sign design contest. The victors are Kelsey Hazzard, ... law school this fall at the University of Virginia, and Christina ...
Cached Medicine News:Health News:Plastic Surgeons Stay Busy in Recession 2Health News:Plastic Surgeons Stay Busy in Recession 3Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 3Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 4Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 5Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 6Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 7Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... is recommended for separations of DNA fragments ... that are easy to handle, and remains ... minimizes the risk of cracking or breaking. ... (GQT) products with similar sieving properties, is ...
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... PK7200 works on patented microplate agglutination ... testing system for donor ABO/Rh testing. PK7200 ... syphilis and cytomegalovirus antibody detection. The Automated ... along with the proven reliability that for ...
Medicine Products: